Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › stage III colon cancer

Stage III colon cancer

Part of Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for stage III colon cancer

3 trials tracked for stage III colon cancer: 1 in phase 3 or 4.

3Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Phase 2 1 Other / NA 1
  1. Phase 3 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed
  2. Phase 2 Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer Completed
  3. N/A Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Preoperative HALP, SII, and LMR scores predict disease-free survival in stage III colon cancer patients
Oncology Cohort
Preoperative HALP, SII, and LMR scores predict disease-free survival in stage III colon cancer patients Blood markers linked to recurrence risk in colon cancer patients
This retrospective cohort study evaluated preoperative HALP, SII, and LMR scores in 210 patients with stage III colon cancer and 220 patient…
A new analysis suggests certain blood markers might help estimate recurrence risk for colon cancer patients after surgery.
Frontiers Apr 29, 2026

Research across Cancer

Related studies from across the Cancer family.

Atezolizumab with mFOLFOX6 Boosts 3-Year DFS by 10.1% in Stage III dMMR Colon Cancer
Oncology RCT
Atezolizumab with mFOLFOX6 Boosts 3-Year DFS by 10.1% in Stage III dMMR Colon Cancer Could a New Treatment Boost Survival for Stage III Colon Cancer Patients?
In a phase 3 trial, atezolizumab plus mFOLFOX6 improved 3-year disease-free survival to 86.3% vs. 76.2% with mFOLFOX6 alone (HR 0.50; 95% CI…
Adding atezolizumab to standard chemotherapy boosted 3-year disease-free survival to 86% in stage III colon cancer patients, up from 76% wit…
Mar 27, 2026